Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Characterization of Novel Aryl-Ether, Biaryl, and Fluorene Aspartic Acid and Diaminopropionic Acid Analogs as Potent Inhibitors of the High-Affinity Glutamate Transporter EAAT2

John Dunlop, H. Beal McIlvain, Tikva A. Carrick, Brian Jow, Qiang Lu, Dianne Kowal, Steven Lin, Alexander Greenfield, Cristina Grosanu, Kristi Fan, Robert Petroski, John Williams, Alan Foster and John Butera
Molecular Pharmacology October 2005, 68 (4) 974-982; DOI: https://doi.org/10.1124/mol.105.012005
John Dunlop
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Beal McIlvain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tikva A. Carrick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Jow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qiang Lu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dianne Kowal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Lin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Greenfield
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristina Grosanu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristi Fan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Petroski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Williams
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Foster
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Butera
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In this study, we describe the pharmacological characterization of novel aryl-ether, biaryl, and fluorene aspartic acid and diaminopropionic acid analogs as potent inhibitors of EAAT2, the predominant glutamate transporter in forebrain regions. The rank order of potency determined for the inhibition of human EAAT2 was N4-[4-(2-bromo-4,5-difluorophenoxy)phenyl]-l-asparagine (WAY-213613) (IC50 = 85 ± 5 nM) > N4-(2′-methyl-1,1′-biphenyl-4-yl)-l-asparagine (WAY-213394) (IC50 = 145 ± 22 nM) = N4-[7-(trifluoromethyl)-9H-fluoren-2-yl]-l-asparagine (WAY-212922) (IC50 = 157 ± 11 nM) = 3-{[(4′-chloro-2-methyl-1,1′-biphenyl-4-yl)carbonyl]amino}-l-alanine (WAY-211686) (IC50 = 190 ± 10 nM). WAY-213613 was the most selective of the compounds examined, with IC50 values for inhibition of EAAT1 and EAAT3 of 5 and 3.8 μM, respectively, corresponding to a 59- and 45-fold selectivity toward EAAT2. An identical rank order of potency [WAY-213613 (35 ± 7 nM) > WAY-213394 (92 ± 13 nM) = WAY-212922 (95 ± 8 nM) = WAY-211686 (101 ± 20 nM)] was observed for the inhibition of glutamate uptake in rat cortical synaptosomes, consistent with the predominant contribution of EAAT2 to this activity. Kinetic studies with each of the compounds in synaptosomes revealed a competitive mechanism of inhibition. All compounds were determined to be nonsubstrates by evaluating both the stimulation of currents in EAAT2-injected oocytes and the heteroexchange of d-[3H]aspartate from cortical synaptosomes. WAY-213613 represents the most potent and selective inhibitor of EAAT2 identified to date. Taken in combination with its selectivity over ionotropic and metabotropic glutamate receptors, this compound represents a potential tool for the further elucidation of EAAT2 function.

  • Received February 14, 2005.
  • Accepted July 13, 2005.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 68 (4)
Molecular Pharmacology
Vol. 68, Issue 4
1 Oct 2005
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of Novel Aryl-Ether, Biaryl, and Fluorene Aspartic Acid and Diaminopropionic Acid Analogs as Potent Inhibitors of the High-Affinity Glutamate Transporter EAAT2
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Characterization of Novel Aryl-Ether, Biaryl, and Fluorene Aspartic Acid and Diaminopropionic Acid Analogs as Potent Inhibitors of the High-Affinity Glutamate Transporter EAAT2

John Dunlop, H. Beal McIlvain, Tikva A. Carrick, Brian Jow, Qiang Lu, Dianne Kowal, Steven Lin, Alexander Greenfield, Cristina Grosanu, Kristi Fan, Robert Petroski, John Williams, Alan Foster and John Butera
Molecular Pharmacology October 1, 2005, 68 (4) 974-982; DOI: https://doi.org/10.1124/mol.105.012005

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Characterization of Novel Aryl-Ether, Biaryl, and Fluorene Aspartic Acid and Diaminopropionic Acid Analogs as Potent Inhibitors of the High-Affinity Glutamate Transporter EAAT2

John Dunlop, H. Beal McIlvain, Tikva A. Carrick, Brian Jow, Qiang Lu, Dianne Kowal, Steven Lin, Alexander Greenfield, Cristina Grosanu, Kristi Fan, Robert Petroski, John Williams, Alan Foster and John Butera
Molecular Pharmacology October 1, 2005, 68 (4) 974-982; DOI: https://doi.org/10.1124/mol.105.012005
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The binding site for KCI807 in the androgen receptor
  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics